BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18798109)

  • 21. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor.
    Bairey O; Shacham-Abulafia A; Shpilberg O; Gurion R
    Hematol Oncol; 2016 Dec; 34(4):184-192. PubMed ID: 26052918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages.
    Jakovic LR; Mihaljevic BS; Andjelic BM; Bogdanovic AD; Perunicic Jovanovic MD; Babic DD; Bumbasirevic VZ
    Leuk Lymphoma; 2016 Aug; 57(8):1839-47. PubMed ID: 26727349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Zhou Q; Wei Y; Huang F; Wei X; Wei Q; Hao X; Zhang Y; Feng R
    Int J Hematol; 2016 Oct; 104(4):485-90. PubMed ID: 27393279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients.
    Li M; Xia H; Zheng H; Li Y; Liu J; Hu L; Li J; Ding Y; Pu L; Gui Q; Zheng Y; Zhai Z; Xiong S
    BMC Cancer; 2019 Nov; 19(1):1084. PubMed ID: 31711453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.
    Bari A; Marcheselli L; Sacchi S; Marcheselli R; Pozzi S; Ferri P; Balleari E; Musto P; Neri S; Aloe Spiriti MA; Cox MC
    Ann Oncol; 2010 Jul; 21(7):1486-1491. PubMed ID: 19920060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
    Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY
    Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma.
    Wei X; Huang F; Wei Y; Jing H; Xie M; Hao X; Feng R
    Leuk Res; 2014 Jun; 38(6):694-8. PubMed ID: 24713260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognosis analysis of primary breast diffuse large B cell lymphoma].
    Zhu YH; Meng WJ; He LH; Jia YS; Tong ZS
    Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):235-240. PubMed ID: 30917462
    [No Abstract]   [Full Text] [Related]  

  • 31. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma.
    Porrata LF; Litzow MR; Inwards DJ; Gastineau DA; Moore SB; Pineda AA; Bundy KL; Padley DJ; Persky D; Ansell SM; Micallef IN; Markovic SN
    Bone Marrow Transplant; 2004 Feb; 33(3):291-8. PubMed ID: 14676784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Useful prognostic tools based on complete blood cell counts in diffuse large B-cell lymphoma.
    Shimono J; Takahashi S; Takemura R; Kakinoki Y
    Int J Lab Hematol; 2019 Dec; 41(6):754-761. PubMed ID: 31529774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Yan-Li L; Kang-Sheng G; Yue-Yin P; Yang J; Zhi-Min Z
    Leuk Res; 2014 Mar; 38(3):323-8. PubMed ID: 24439567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
    Wen JJ; Liu ZB; Xu J; Xu CG
    Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells.
    Lu Y; Zhu H; Liu Y; Wang Y; Sun Y; Cheng H; Yan Z; Cao J; Sang W; Zhu F; Li D; Sun H; Zheng J; Xu K; Li Z
    Front Immunol; 2023; 14():1155216. PubMed ID: 37205117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
    Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
    Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
    Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Porrata LF; Rsitow K; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Colgan JP; Nowakowski GS; Thompson CA; Markovic SN
    Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.